Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ATAC-seq analysis of wild-type Jurkat, SV engineered Jurkat, DND-41 and LOUCY leukemia cell lines

ABSTRACT: ATAC-seq analysis of wild-type Jurkat, SV engineered Jurkat, DND-41 and LOUCY leukemia cell lines

PROVIDER: PRJNA821189 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18518478.fastq.gz	Fastqsanger.gz
	SRR18518479.fastq.gz	Fastqsanger.gz
	SRR18518480.fastq.gz	Fastqsanger.gz
	SRR18518481_1.fastq.gz	Fastqsanger.gz
	SRR18518481_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 11

Similar Datasets

ATAC-seq from DND-41 (ENCSR660WSB)

Project description:ATAC-seq on human cell line DND-41 For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf

2021-04-22 | GSE172903 | GEO

ATAC-seq analysis of wild-type Jurkat, SV engineered Jurkat, DND-41 and LOUCY leukemia cell lines

Project description:Structural variants (SVs) involving enhancer hijacking can disrupt chromatin topologies to cause oncogene activation in cancer genomes, yet the molecular determinants for the transcriptional output of enhancer hijacking remain largely unknown. We developed a multimodal approach to integrate genome sequencing, chromosome conformation, and sequence-based deep learning for quantitative analysis of transcriptional effects and structural reorganization imposed by SVs in leukemic genomes. We identified candidate pathogenic SVs including recurrent t(5;14) translocations that cause the hijacking of BCL11B enhancers for oncogenic activation of TLX3-dependent transcriptional programs. By engineering patient-associated t(5;14) in isogenic leukemia cells, we uncovered an uncharacterized mechanism whereby DNA methylation serves as an epigenetic barrier to enhancer hijacking and loss of epigenetic barrier is a molecular determinant for the transcriptional output of pathogenic SVs. Hence, leveraging the epigenetic barriers of SV-mediated oncogenic programs may provide new opportunities to reprogram gene regulation as epigenetic therapies in human disease.

2023-04-25 | GSE199691 | GEO

Cut&Run analysis for transcription factors in DND-41 cells

Project description:Cut&Run analysis was performed in DND-41 cells to analyze the basal level of H3K27ac and DNA bindings of BRG1 and RUNX1 after DMSO or ACBI-1 treatment.

2024-07-02 | GSE230593 | GEO

H3K27ac Hi-ChIP analysis in MOLT-4 and DND-41 cells.

Project description:H3K27ac Hi-ChIP analysis was performed in MOLT-4 and DND-41 cells to analyze active chromatin-chromatin interactions after DMSO or ACBI-1 treatment.

2024-07-02 | GSE230591 | GEO

ATAC-seq analysis for DND-41 and MOLT4 cells with ACBI-1 treatment

Project description:ATAC-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) with either DMSO or ACBI-1 treatment at two different time points (3hr and 24hr).

2024-07-02 | GSE230584 | GEO

RNA-seq analysis after 24hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 24 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230590 | GEO

RNA-seq analysis after 8hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 8 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230589 | GEO

RNA-seq analysis after 3hr of ACBI-1 treatment on DND-41 and MOLT-4 cells.

Project description:RNA-seq analysis was performed in two T-ALL cell lines (DND-41 and MOLT-4) to analyze gene expression changes after 3 hours of 100nM ACBI-1 or DMSO treatment.

2024-07-02 | GSE230588 | GEO

CRISPR/Cas9 screen of T-ALL cells (DND-41) in the presence of DMSO, CB-103 or GSI (DAPT).

Project description:The efficacy of targeted therapies for treatment of cancer patients is often limited by development of drug resistance. Potential resistance mechanisms to pharmacological Notch1 inhibition mediated by GSI or CB-103 in T-ALL are currently unclear. Thus, we performed a genome-wide loss-of-function (LoF) CRISPR/Cas9 screen to identify genes responsible for resistance to Notch inhibition and novel combination therapies for efficient treatment of human T-ALL. We used a Notch-dependent human T-ALL cell line, DND-41, which responds moderately to both GSI and CB-103 treatment in vitro. DND-41 cells stably expressing Cas9 were infected with human GeCKO v2 CRIPSR libraries, containing 123,411 sgRNAs targeting 19,050 genes and treated with either vehicle, GSI or CB-103 for 21 days enabling both positive and negative selection of sgRNAs.

2023-06-26 | GSE221576 | GEO

mRNA-seq of DND-41 T-cell acute lymphoblastic leukemia cell line upon inhibition of hsa-miR-363-3p

Project description:The aim of this study was to investigate the effect of hsa-miR-363-3p on global gene expression in T-cell acute lymphoblastic leukemia (T-ALL). For this purpose we selected DND-41 T-ALL cell line characterized by high expression of this miRNA. The cells were transduced either with miRZip pGreenPuro scrambled vector (System Biosciences) or miRZip anti-hsa-miR-363-3p vector, each variant in three biological replicates. All 6 libraries were sequenced on Illumina NovaSeq6000 platform, in 2x150 mode, with a coverage of 60M paired reads/sample.

2022-04-30 | E-MTAB-11366 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data